RESUMEN
OBJECTIVE: To investigate the effect of SH2-containing inositol phosphatase-1 (SHIP-1) on the proliferation, invasion and migration of human leukemia cells as well as phosphatidylinositol-3 kinase (PI3K) / protein kinase B (AKT) signaling pathway. METHODS: The overexpression vector pCDNA3.1-SHIP1 was transfected into THP-1 cells by Lipofectamine 2000. The experiment was divided into 3 groups: control group (untreated cells) and empty vector group (transfected with empty vector pCDNA3.1-NC) and overexpression group (transfected with overexpression vector pCDNA3.1-SHIP1). The cell proliferation was tected by CCK-8 assay, Transwell assay was used to evaluate the cell invasion and migration capabilities. The expressions of SHIP-1, AKT, phosphorylated AKT (pAKT), matrix metalloproteinase-9 (MMP-9) protein were analyzed by Western blot. RESULTS: The expression of SHIP-1 in overexpression group was significantly higher than that in the control group(P<0.05). Compared with the control group, the absorbance of the cells in the empty vector group was not statistically different (P>0.05), and the absorbance in overexpression group decreased significantly(P<0.05). The cell numbers of invasion and migration were not significantly different between empty and control groups(P>0.05), but those in overexpression group were significantly lower than those in the control group(P<0.05). Compared with the control group, the expression of AKT, pAKT and MMP-9 in the empty vector group was not statistically different (P>0.05); the AKT protein in overexpression group was not significantly different (P>0.05), but the pAKT and MMP-9 significantly decreased(P<0.05). CONCLUSION: SHIP-1 plays a role in inhibiting the proliferation, invasion and migration of leukemia cells, the mechanism probably relates with supressing the expression of MMP-9 by regulating PI3K/AKT signaling pathway.
Asunto(s)
Transducción de Señal , Línea Celular Tumoral , Movimiento Celular , Proliferación Celular , Humanos , Invasividad Neoplásica , Fosfatidilinositol 3-Quinasas , Fosfatidilinositol-3,4,5-Trifosfato 5-Fosfatasas , Proteínas Proto-Oncogénicas c-aktRESUMEN
OBJECTIVE: To investigate the change of plasma IL-16 level in patients with multiple myeloma(MM) and its clinical significance. METHODS: Sixty-two patients with multiple myeloma were admitted in our hospital from June 2008 to June 2015. Forty healthy volunteers were selected as control group. The peripheral blood of all the patients and healthy volunteers were collected before the treatment of patients. The levels of IL-16, Cys-C, LDH and ß2-MG were measured. ROC curve was used to analyze the optimal IL-16 thresholds in MM patients. Kaplan-Meier method was used to analyze the factors affecting overall survival. RESULTS: The levels of IL-16, Cys-C, LDH and ß2-MG in the MM group were significantly higher than those in the control group (P<0.05). The levels of IL-16, Cys-C, LDH and ß2-MG in patients with different ISS were significantly different (P<0.05). The levels of IL-16, Cys-C, LDH and ß2-MG in ISS III groups were higher than those in ISS I and ISS II groups(P<0.05). When the IL-16 concentration was 171.26 ng/L, the AUC was 0.787 (P<0.01), and the sensitivity and specificity were 82.25% and 75.80%, respectively, when the IL-16 threshold was predicted by ROC curve analysis. The 3-year overall survival rates of patients with IL-16≤171.26 ng/L and IL-16>171.26 ng/L were 91.93% and 51.61%, respectively (P<0.01). Multivariate analysis showed that the changes of IL-16 levels were significantly related with overall survival (P<0.01). CONCLUSION: The level of IL-16 in peripheral blood of patients with multiple myeloma has been cofirmed to be significantly elevated, and the elevated IL-16 is closely related with the prognosis.
Asunto(s)
Biomarcadores de Tumor/metabolismo , Interleucina-16/metabolismo , Mieloma Múltiple/diagnóstico , Humanos , Interleucina-6 , Mieloma Múltiple/metabolismo , Pronóstico , Sensibilidad y Especificidad , Tasa de SupervivenciaRESUMEN
OBJECTIVE: To compare the effects of different dosages of rhG-CSF on duration of aleucocytosis and white blood cell counts after chemotherapy of patients with hematologic malignancies. METHODS: Ninety patients in our hospital from December 2011 to June 2016 were chosen as study objects, and all of them were divided into 3 groups: group A (rhG-CSF 200 µg/m2), group B(rhG-CSF 300 µg/m2) and group C(rhG-CSF 400 µg/m2); 30 patients from January 2004 to January 2007 were chosen as control(control group). The WBC(min) and its duration, WBC(max) and its timepoint were compared among different groups. The infection rate, incidence of side reactions and total amount of rhG-CSF used in different groups were compared. RESULTS: In control group, WBC(min) was(1.30±0.11)×109/L, its duration was (3.2±0.7)d, WBC(max) was(5.14±0.41)×109/L, and its time point was (26.1±1.8)d; these in group A were (3.14±0.23)×109/L,(2.7±1.0)d, (10.08±0.69)×109/L and (14.9±1.8)d respectively; these in group B were (3.11±0.32)×109/L, (0.9±0.5)d, (10.17±0.75)×109/L and(10.7±1.5)d respectively; these in group C were (3.15±0.30)×109/L,(0.5±0.3)d, (11.95±0.86)×109/L and (10.6±1.5)d, respectively. Compared with control group, the WBC(min) and WBC(max) were both increased significantly, the duration of WBC(min) was shortened and the timepoint of WBC(max) was moved up(P<0.05). The infection rate of group C (3.33%(1/30)) was significantly lower than that of control group(33.33%(10/30))(P<0.05), total used amount of rhG-CSF and incidence of side reactions were not statistically different among group A,B,C(P>0.05). CONCLUSION: Compared with low dosage of rhG-CSF, medium/high dosage of rhG-CSF can help to shorten duration of a leukocytosis after chemotherapy of patients.